Leadership Overview
Takeda Oncology has 5 executives leading key functions including finance, operations, and global oncology strategy.
Driven by a commitment to patient well-being, Takeda Oncology advances innovative cancer therapies, aiming to transform lives through cutting-edge research and development in the global pharmaceutical landscape.
Driven by a commitment to patient well-being, Takeda Oncology advances innovative cancer therapies, aiming to transform lives through cutting-edge research and development in the global pharmaceutical landscape.
Leadership Roles at Takeda Oncology
Marcelo Barretta - Chief Financial Officer
Marcelo Barretta, the Chief Financial Officer at Takeda Oncology, directs all financial operations and strategic fiscal planning. Overseeing budgeting, forecasting, and financial reporting, Barretta ensures robust financial health for the oncology business unit. This leadership involves managing investment strategies and optimizing resource allocation to support Takeda Oncology's global development and production of cancer therapies. By maintaining stringent financial controls and identifying growth opportunities, Marcelo Barretta drives fiscal responsibility and contributes directly to the company's mission of developing life-changing oncology treatments. The Chief Financial Officer's role is critical in securing the financial stability necessary for sustained innovation and market expansion in the competitive pharmaceutical sector.
Rob Smith - President
Rob Smith, the President at Takeda Oncology, spearheads the strategic direction and overall performance of the oncology business unit. Smith directs global operations, focusing on advancing the development and commercialization of innovative cancer therapies. This leadership position involves fostering a culture of scientific excellence and patient-centricity, ensuring Takeda Oncology remains at the forefront of cancer treatment innovation. By guiding strategic partnerships and market expansion initiatives, Rob Smith drives the company's commitment to transforming the lives of patients globally. The President's oversight encompasses all facets of the oncology business, from research and development to market access, ensuring alignment with Takeda Pharmaceutical's broader mission.
Teresa Bitetti - Global President, Oncology Business Unit
Teresa Bitetti, the Global President, Oncology Business Unit at Takeda Oncology, leads the strategic vision and execution for all global oncology operations. Bitetti drives the development and commercialization of Takeda's innovative cancer therapies, focusing on delivering significant value to patients worldwide. This executive role involves overseeing research, clinical development, regulatory affairs, and market access strategies to ensure Takeda Oncology's pipeline advances effectively. By championing patient needs and fostering strong collaborations, Teresa Bitetti guides the organization toward achieving its mission of conquering cancer. The Global President, Oncology Business Unit's leadership is pivotal in expanding access to life-changing treatments and solidifying Takeda Oncology's position as a leader in the fight against cancer.
Christophe Bianchi - President
Christophe Bianchi, the President at Takeda Oncology, directs the strategic initiatives and operational execution for the oncology business unit. Bianchi focuses on advancing the company's portfolio of groundbreaking cancer therapies, ensuring their development and delivery to patients globally. This leadership role emphasizes scientific innovation and a deep commitment to addressing unmet medical needs in oncology. By fostering strategic alliances and optimizing market penetration, Christophe Bianchi drives Takeda Oncology's mission to improve patient outcomes and quality of life. The President's purview includes guiding research efforts, commercial strategies, and ensuring operational excellence across all functions critical to Takeda Oncology's success in the pharmaceutical industry.
Tawnee Friedrich - Chief Of Staff, GMAO
Tawnee Friedrich, the Chief Of Staff, GMAO at Takeda Oncology, provides strategic operational support and drives key initiatives across the Global Medical Affairs and Operations (GMAO) division. Friedrich coordinates cross-functional projects, enhances operational efficiency, and ensures seamless execution of strategic plans. This role involves close collaboration with senior leadership to align departmental objectives with Takeda Oncology's overarching mission of developing and delivering innovative cancer therapies worldwide. By streamlining processes and fostering effective communication, Tawnee Friedrich enables the GMAO team to accelerate the development and accessibility of critical oncology treatments. The Chief Of Staff, GMAO's focus is on optimizing organizational performance and facilitating the strategic deployment of resources to achieve Takeda Oncology's ambitious goals.
Explore Leadership Teams in Manufacturing
GSK plc is a British multinational pharmaceutical and biotechnology company headquartered in London, United Kingdom. Established in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham, GSK is the tenth-largest pharmaceutical company globally. The company discovers, develops, manufactures, and delivers medicines and vaccines with a research and development focus on four primary therapeutic areas: respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. GSK's product portfolio includes specialty medicines, vaccines, and general medicines targeting conditions such as HIV, respiratory diseases, cancer, immuno-inflammation, anti-viral, central nervous system disorders, metabolic conditions, cardiovascular disease, urogenital conditions, anti-bacterial treatments, dermatology, and rare diseases. The company also offers over-the-counter products for pain relief, oral health, nutrition, skin health, and gastrointestinal diseases. GSK has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. In July 2024, the company moved its global headquarters to New Oxford Street in central London, positioning itself within the city's Knowledge Quarter near world-class science and academic institutions including the Francis Crick Institute and King's College London. The new headquarters houses approximately 3,000 employees including the global leadership team and teams supporting research and development, supply chain, commercial operations, and corporate functions. GSK sells its products through wholesalers, pharmacies, hospitals, physicians, and other healthcare groups globally, aiming to positively impact the health of 2.5 billion people by the end of the decade.
Company Leadership JP
SS
DW
SN
Merz is a privately held pharmaceutical company based in Frankfurt, Germany with affiliates across Europe, as well as the US, Canada, Mexico, Brazil, and Asia Pacific. The company is active in research, development, and distribution of innovative products in the areas of aesthetic medicine and neurologically induced movement disorders.
Company Leadership LP
KH
WF
CG
Founded in 1850 and headquartered in Johannesburg, South Africa, Aspen Pharmacare Holdings Limited is a global specialty and branded pharmaceutical company headquartered in Durban, South Africa. Operating across Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia, Aspen focuses on sterile injectables (including anaesthetics, anticoagulants, antithrombotics, analgesics, and hormone replacement therapies), over-the-counter medicines, and prescription products for conditions such as hypothyroidism, autoimmune disease, pain, gout, and inflammatory disorders. The company also manufactures active pharmaceutical ingredients and finished dose forms, including steriles, oral solids, liquids, semi-solids, biologicals, and heparins, supplying both its own brands and third-party customers worldwide.
Company Leadership
TS
RM
SC
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.
Company Leadership
AL
JS
MA
Frequently Asked Questions Regarding Takeda Oncology Top Executives and Leadership Team
